Moderna, Inc. NMS · MRNA

Clinical Stage Partnering Terms and Agreements in Pharmaceuticals and Biotechnology 2020-2026 | Benchmark More Than 1,800 Biopharma Deals with Various Indexes

GlobeNewswire Inc. · 15h ago

Vertex Pharmaceuticals Just Made a $10 Billion Move. Is the Stock a Buy?

The Motley Fool · 7d ago

Moderna Stock Is Soaring. Is It Too Late to Buy?

The Motley Fool · 10d ago

These 3 Stocks Trounced the S&P 500 in the First Half of 2026 -- and Wall Street Thinks 1 of Them Could Soar Even More

The Motley Fool · 11d ago

Fidelity Health Care vs. State Street Biotech: Which ETF Fits Your Portfolio Best?

The Motley Fool · 12d ago

Biogen Is Paying $1 Billion for a Company That Won't Say What It Makes. Here's Why That's Actually Good News for BIIB Investors.

The Motley Fool · 13d ago

Moderna vs. Recursion: Which Cutting-Edge Pharma Stock Is a Better Buy in 2026?

The Motley Fool · 14d ago

Moderna Stock’s Short Squeeze Fades: 3 Key Support Levels to Watch

Investing.com · 16d ago

Is Moderna Stock a No-Brainer Buy After a Key FDA Win?

The Motley Fool · 17d ago

Big Pharma Has a Case of Merger Mania

The Motley Fool · 17d ago

Should You Buy Moderna Before Aug. 5?

The Motley Fool · 25d ago

Moderna Has Some Key Approvals Ahead. Is the Stock a Buy?

The Motley Fool · 27d ago

These 3 Stocks Have Crushed the Market This Year. Here's Why There Is More Upside Ahead

The Motley Fool · 29d ago

FDA Panel Set To Debate Moderna Flu Shot

Benzinga · 30d ago

Stock Market Today, June 16: Nvidia, Broadcom, and Micron Technology Lead Drop in Nasdaq

The Motley Fool · 31d ago

Dow Jones Hit Record Highs As Oil Drops To $77: Stock Market Today

Benzinga · 31d ago

Moderna Strengthens Commercial Strategy As Pipeline Advances

Benzinga · 31d ago

Parabilis Soared 58% in the Biggest Biotech IPO on Record. Is It Too Late to Buy the Stock?

The Motley Fool · 35d ago

Does Moderna Need to Start Making Money?

The Motley Fool · 38d ago

Broadcom’s Guidance Miss Exposes the Fragility of the AI Trade

Investing.com · 43d ago

Moderna Reports Strong 5-Year Cancer Vaccine Data, Expands CEPI Partnership; Stock Falls

Benzinga · 46d ago

Anterix Stock Is Up 140%. Here's Why One Investor Just Bought $15.8 Million

The Motley Fool · 49d ago

Synovial Sarcoma Clinical Trial Pipeline Accelerates as 15+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

GlobeNewswire Inc. · 50d ago

CytomX Therapeutics to Present at Upcoming June Investor Conferences

GlobeNewswire Inc. · 57d ago

3 Reasons Not to Buy Into the Hantavirus-Related Biotech Rally

The Motley Fool · 65d ago